Companies: 10,795·Total market cap: $144.5T
CRISPR Therapeutics AG

CRISPR Therapeutics AG

CRSPNASDAQHealthcare● Active
$51.92
+$0.08(+0.15%)
Market Cap$5.0B
P/E Ratio
52W High$78.48
52W Low$37.02
SEC Filings
Foreign Private Issuer · Files 20-F / 6-K

CRISPR Therapeutics AG (CRSP) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001674416 · CRSP · NASDAQ · as of Jun 8, 2026

Filing snapshot

843
Total Filings
S-8
Latest Form
2026-06-05
Most Recent
2016
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001674416 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-02-12
Fiscal Year End
Feb 12, 2026
Accession No.
0001193125-26-048957
Primary Document
crsp-20251231.htm
Source: data.sec.gov · CIK 0001674416 · Accession 0001193125-26-048957

Latest Key Filings

6-KQuarterly Report

No recent filings

8-KCurrent Report
8-K
2026-06-04Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
S-8Employee Stock Plan Registration
S-8
2026-06-05
View
8-KCurrent Report
8-K
2026-06-04
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-05-14
View
10-QQuarterly Report
10-Q
2026-05-04
View
8-KCurrent Report
8-K
2026-05-04
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-04-30
View
ARSARS
ARS
2026-04-21
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-21
View
DEF 14AProxy Statement
DEF 14A
2026-04-21
View
PRE 14APRE 14A
PRE 14A
2026-04-02
View
8-KCurrent Report
8-K
2026-03-16
View
8-KCurrent Report
8-K
2026-03-11
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-17
View
10-KAnnual Report
10-K
2026-02-12
View
Showing 1–15 of 390 filingsForm 4 / 144 hidden· 843 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001674416  |  Exchange: NASDAQ · Healthcare

CRISPR Therapeutics AG (NASDAQ: CRSP) has submitted 843 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2016. As a Healthcare sector company with CIK 0001674416, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is CRISPR Therapeutics AG's most comprehensive regulatory disclosure. The most recent CRISPR Therapeutics AG 10-K was filed on 2026-02-12 for fiscal year ending 2026. Historical CRSP 10-K annual reports are available from 2016 through 2026.

Investors researching CRISPR Therapeutics AG SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08

Frequently Asked Questions

CRSP SEC Filings · 8 questions

CRISPR Therapeutics AG (CRSP) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 843 filings and access original documents at no cost. CRISPR Therapeutics AG's CIK is 0001674416.

CRSP SEC filingsCRISPR Therapeutics AG SEC documentsfind CRSP 10-K